Your browser doesn't support javascript.
loading
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.
Fessas, Petros; Naeem, Muntaha; Pinter, Matthias; Marron, Thomas U; Szafron, David; Balcar, Lorenz; Saeed, Anwaar; Jun, Tomi; Dharmapuri, Sirish; Gampa, Anuhya; Wang, Yinghong; Khan, Uqba; Muzaffar, Mahvish; Navaid, Musharraf; Lee, Pei-Chang; Bulumulle, Anushi; Yu, Bo; Paul, Sonal; Nimkar, Neil; Bettinger, Dominik; Hildebrand, Hannah; Abugabal, Yehia I; Pressiani, Tiziana; Personeni, Nicola; Nishida, Naoshi; Kudo, Masatoshi; Kaseb, Ahmed; Huang, Yi-Hsiang; Ang, Celina; Pillai, Anjana; Rimassa, Lorenza; Naqash, Abdul Rafeh; Sharon, Elad; Cortellini, Alessio; Pinato, David J.
Afiliação
  • Fessas P; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.
  • Naeem M; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.
  • Pinter M; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Vienna Liver Cancer Study Group, AKH and Medical University of Vienna, Vienna, Austria.
  • Marron TU; Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
  • Szafron D; Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Balcar L; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Vienna Liver Cancer Study Group, AKH and Medical University of Vienna, Vienna, Austria.
  • Saeed A; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, Kansas, USA.
  • Jun T; Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
  • Dharmapuri S; Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
  • Gampa A; Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago Medicine, Chicago, Illinois, USA.
  • Wang Y; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Khan U; Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA.
  • Muzaffar M; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Navaid M; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Lee PC; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Bulumulle A; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Yu B; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Paul S; Lincoln Medical Center, New York, New York, USA.
  • Nimkar N; New York Presbyterian Brooklyn Methodist Hospital, New York, New York, USA.
  • Bettinger D; New York Presbyterian Brooklyn Methodist Hospital, New York, New York, USA.
  • Hildebrand H; Department of Medicine II, Faculty of Medicine, Medical Center University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Abugabal YI; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, Kansas, USA.
  • Pressiani T; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Personeni N; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center IRCCS, Milan, Italy.
  • Nishida N; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center IRCCS, Milan, Italy.
  • Kudo M; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Kaseb A; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Huang YH; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Ang C; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pillai A; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Rimassa L; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Naqash AR; Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
  • Sharon E; Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago Medicine, Chicago, Illinois, USA.
  • Cortellini A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center IRCCS, Milan, Italy.
  • Pinato DJ; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Liver Cancer ; 10(6): 583-592, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34950181
ABSTRACT
BACKGROUND AND RATIONALE Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indications; however, the effect of ATB is undefined in HCC.

METHODS:

In a large international cohort of 450 ICI recipients from Europe, North America, and Asia, we categorized patients according to timing of ATB focusing on exposure within -30 to +30 days from ICI (early immunotherapy period [EIOP]). EIOP was evaluated in association with overall survival (OS), progression-free survival (PFS), and best radiologic response using RECIST 1.1 criteria.

RESULTS:

Our study comprised mostly cirrhotic (329, 73.3%) males (355, 79.1%) with a Child-Turcotte Pugh class of A (332, 73.9%), receiving ICI after 1 therapy line (251, 55.9%) for HCC of Barcelona clinic liver cancer stage C (325, 72.4%). EIOP (n = 170, 37.9%) was independent of baseline clinicopathologic features of HCC and correlated with longer PFS (6.1 vs. 3.7 months, log-rank p = 0.0135). EIOP+ patients had similar OS, overall response, and disease control rates (DCRs) compared to EIOP. The effect of EIOP persisted in landmark time analyses and in multivariable models, confirming the independent predictive role of EIOP in influencing PFS following adjustment for covariates reflective of tumor burden, liver function, and ICI regimen administered. In patients receiving programmed cell death-1 receptor/ligand inhibitors monotherapy, EIOP was also associated with higher DCRs (61.4% vs. 50.9%, p = 0.0494).

CONCLUSIONS:

Unlike other oncological indications, ATB in the 30 days before or after ICI initiation is associated with improved benefit from immunotherapy, independent of disease and treatment-related features. Evaluation of the immune microbiologic determinants of response to ICI in HCC warrants further investigation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article